FDA 483与警告信:Somerset Therapeutics无菌药品生产被指LIMS数据转移及浮游菌采样记录不完整
FDA483:lims设计上刻意筛选数据,浮游十几次中断无法解释最终还上了警告信
Somerset Therapeutics无菌药品生产在FDA检查后收到警告信,483列出LIMS杂质数据未完整转移、浮游菌采样中断等记录完整性问题。检查日期为2025年2月10日至21日,FEI 3003821988;文章称警告信于2025年9月发出。作者逐条点评观察项8和10,并摘录警告信对空气采样器数据保存、计算机系统完整性评估及CAPA的要求。
本文中观点不代表任何公司和组织,如有觉得有冒犯的地方,请于后台联系,我会及时删除。所有分享案例都具有孤立性,仅供参考。
·企业名称 / Firm Name:Somerset Therapeutics Private Limited
·检查日期 / Date(s) of Inspection:2025 年 2 月 10 日至 2 月 21 日 / 02/10/2025 – 02/21/2025
·FEI 编号 / FEI Number:3003821988
·检查类型 / Type Establishment Inspected:无菌药品生产商 / Sterile Drug Manufacturer
·签发日期 / Date Issued:2025 年 2 月 21 日 / 02/21/2025
检查员:
Eileen A. Liu, Investigator (Lead) / Eileen A. Liu,检查员(组长)
Joseph A. Piechocki, Investigator / Joseph A. Piechocki,检查员
检查结果:OAI 2025年09月被发放警告信
……
观察项 8 / Observation 8
Batch production and control records do not include complete information relating to the production and control of each batch. Specifically,
批生产及质量控制记录未包含与每批产品生产和控制相关的完整信息。具体如下:
A. There is no assurance that all active air sample data obtained using xxx air samplers are reviewed and complete as part of the batch production record. Active air samples are obtained throughout the filling area within the filling line (fixed equipment) and the filling area (portable equipment) following QCB-050, "Environmental Monitoring Programme" and QCB-091, "Environmental Monitoring Programme for xxx Line xxx". However, upon review of the electronic data associated with xxx of the xxx air samplers, 17 aborted runs were observed, including air samples collected within the xxx areas and corridors. According to your microbiology personnel, these aborted runs are associated with samples which were collected, however the person collecting these samples did not visually ensure that the air sample was completed for the entire xxx collection time, and these electronic data logs are not reviewed as part of the batch record.
A. 无法保证使用 xxx 空气采样器获得的所有主动空气采样(浮游菌)数据均已审核并作为批生产记录的组成部分保持完整。主动空气采样按照 QCB-050《环境监测方案》和 QCB-091《xxx 灌装线环境监测方案》,在灌装线内灌装区域(固定设备)和灌装区域(便携设备)全程进行。然而,在审核与 xxx 台 xxx 空气采样器相关的电子数据时,观察到 17 次中止的运行,包括在 xxx 区域和走廊内采集的空气样品。根据你方微生物人员所述,这些中止的运行与已采集的样品相关,但采集样品的人员未目视确认空气采样在整个 xxx 采集时间内完成,且这些电子数据日志不作为批记录的一部分进行审核。
西门:这一段浮游菌采样中断,虽然多,但浮游不像粒子造假来的那么直接和刻意,毕竟粒子实时可以看到结果,而且很容易超,所以中断多,可以质疑其厂房密闭系统等。又因为浮游仅仅是一个泵,就一个启停,所以一般也不认为是GMP数据,设备也不作为计算机化系统管理……
但我万万没想到FDA最后抓住这条不放,最后落在了警告信的第一条里,详见文末摘录自其警告信相关内容。当然这里可能是无菌模拟灌装的失败,以及厂区长期存在菌污染……
B. In-process xxx are performed and documented by production and IPQA personnel at set intervals, as defined within the respective batch records. However, the Filling Line xxx are equipped with xxx which are not required to be used during filling. In addition, the xxx reports included as part of the batch record were reviewed for xxx Injection USP xxx mg/mL xxx mL) Batch xxx, xxx Injection USP xxx mL xxx mg/mL) Batches xxx (Exhibit Batch for xxx) and xxx Injection USP xxx Units, xxx mL xxx Units/mL) and Batch xxx (Exhibit Batch for xxx). However, xxx obtained by the xxx during the filling process were found to be out of the xxx limits. There was no investigation initiated for these xxx and there is also no procedural requirement to ensure these xxx are used and the data associated are reviewed.
B. 过程(中控)xxx 由生产和 IPQA(过程质量保证)人员按各批记录中规定的设定间隔执行并记录。然而,灌装线 xxx 配备的 xxx 在灌装期间并非强制要求使用。此外,对以下批次批记录中作为组成部分的 xxx 报告进行了审核:xxx 注射剂 USP(xxx mg/mL,xxx mL)批次 xxx、xxx 注射剂 USP(xxx mL,xxx mg/mL)批次 xxx(xxx 的展示批)以及 xxx 注射剂 USP(xxx 单位,xxx mL xxx 单位/mL)和批次 xxx(xxx 的展示批)。然而,灌装过程中由 xxx 获得的 xxx 被发现超出 xxx 限度。这些 xxx 未启动任何调查,且亦无程序要求确保这些 xxx 得到使用并审核相关数据。
C. Filling Line xxx is equipped with various detect functions, including "Safety xxx det" (for detection of filling line xxx), and "Grating detection" (for use of the gloves near the filling zone). However, there is no procedural or automated control to ensure that the correct detect functions are used and the data collected during the filling of a batch is complete. In addition, Filling Line xxx is equipped with alarms, including xxx alarms. These alarms are not captured or reviewed as part of the batch report.
C. 灌装线 xxx 配备多种检测功能,包括"安全 xxx 检测"(用于检测灌装线 xxx)和"格栅检测"(用于灌装区附近手套的使用)。然而,没有程序性或自动化控制来确保使用正确的检测功能,并确保批灌装期间收集的数据完整。此外,灌装线 xxx 配备各种报警,包括 xxx 报警。这些报警未作为批报告的一部分进行捕获或审核。
……
观察项 10 / Observation 10
Laboratory records do not include complete data derived from all tests, examination and assay necessary to assure compliance with established specifications and standards. Specifically,
实验室记录未包含所有为保证符合既定质量标准与规范所必需的检验、检查和测定所得的全部数据。具体如下:
A. Laboratory results within the LIMS system are not adequately verified to ensure that data obtained from the chromatography system are appropriately reported. For example, the total impurities related to stability testing of xxx Injection, USP xxx drug product Batches xxx (18 month, Long Term, Inverted), xxx (Expiry Month, Room Temperature, Inverted), xxx (Expiry Month, Room Temperature, Upright), xxx (Expiry Month, Room Temperature, Inverted), xxx (12 month, Accelerated, Inverted), and xxx (12 Month, Long Term, Upright) were reported within LIMS as xxx%, xxx%, xxx%, xxx%, xxx%, and xxx%, respectively. However, review of the data obtained in the Empower chromatography system did not adequately transfer all unknown impurities to the LIMS which were above the quantitation limit, and therefore the reported results should have been xxx%, xxx%, xxx%, xxx%, xxx%, xxx%, respectively.
A. 实验室信息系统(LIMS)中的实验室结果未得到充分核实,以确保色谱系统获得的数据得到恰当报告。例如,xxx 注射剂 USP xxx 药品批次 xxx(18 个月,长期,倒置)、xxx(效期月,室温,倒置)、xxx(效期月,室温,正立)、xxx(效期月,室温,倒置)、xxx(12 个月,加速,倒置)和 xxx(12 个月,长期,正立)的总杂质在 LIMS 中报告分别为 xxx%、xxx%、xxx%、xxx%、xxx% 和 xxx%。然而,对 Empower 色谱系统所获数据的审核表明,高于定量限的所有未知杂质未充分转移至 LIMS,因此报告结果应分别为 xxx%、xxx%、xxx%、xxx%、xxx% 和 xxx%。
西门的备注:LIMS从色谱系统中抓取数据,无非两种,接口直连其数据库或者文本型pdf中抓取字段(maybe正则定位),这里既然没抓错,那就代表是刻意筛,也就是一开始设计就刻意过滤了
B. The documentation related to the antimicrobial assay of xxx drug substance and xxx Injection, USP xxx is not complete. The assay testing requires the drug substance test sample and reference standards to be dried and cooled in a desiccator containing xxx and maintaining at NMT xxx% RH prior to further preparation as the material is highly hygroscopic and is therefore prepared on a dried basis. The test record documenting the execution of the assay does not include verification of desiccant and humidity as well as cooling times to ensure the sample was adequately dried following the procedure.
B. 与 xxx 原料药和 xxx 注射剂 USP xxx 抗菌(效价)测定相关的文件不完整。该测定检验要求原料药供试品和对照品(参考标准品)在进一步制备前,置于装有 xxx 的干燥器中干燥并冷却,且保持相对湿度(RH)不超过 xxx%,因为该物料吸湿性极强,因此按干燥品(干基)制备。记载该测定执行情况的检验记录未包含对干燥剂和湿度以及冷却时间的核实,以确保样品按程序充分干燥。
西门的备注:早先我从QC转型CS后,一开始主要是做实验室生态链,当时ELN设计一个很大的思路就是,实验记录里提及时间的必须被抓取,并能被系统判定是否满足要求,以及不能跳步,这也是ALCOA,中C的一个直观体现。
C. Laboratory records do not ensure that the correct glassware is used during standard and sample preparation. For example xxx Injection, USP requires standards and samples to be prepared in xxx glassware. The use of this glassware is not documented in any Quality Control testing records for testing this drug product, including in the LIMS software.
C. 实验室记录无法确保标准品和样品制备过程中使用了正确的玻璃器皿。例如,xxx 注射剂 USP 要求标准品和样品在 xxx 玻璃器皿中制备。在检验该药品的任何质量控制检验记录(包括 LIMS 软件中)中,均未记录该玻璃器皿的使用情况。
西门的备注:玻璃器皿一般是耗材,哪怕是定量类的比如容量瓶,这里要求记录其使用情况,让人很费解,真的有必要么
C. You failed to review electronic data from (b)(4) air samplers used for environmental monitoring and ensure a timely and appropriate investigation of numerous aborted air sampler events. During the inspection, we identified at least 16 aborted air samples collected over (b)(4) in February 2025, within the (b)(4) areas and corridors. The review of aborted air sampler data was limited by its unacceptable data retention capability of only 115 entries.
C. 您未能对用于环境监测的(b)(4)项空气采样器的电子数据进行检查,也没有及时对众多失败的空气采样事件进行妥善处理。在检查过程中,我们发现了至少 16 个在 2025 年 2 月于(b)(4)区域内采集到的失败的空气样本数据。由于空气采样器数据的存储能力有限,只能存储 115 条记录,因此对这些失败采样数据的审查工作受到了限制。
Your response is inadequate. You state that the “(b)(4)” of the (b)(4) organisms used to validate your (b)(4) sterilization cycle is greater than the “(b)(4)” of the B. cereus organisms identified in the contaminated media. Although B. cereus is typically known to exhibit less (b)(4) than (b)(4), B. cereus is also known to have a relatively wide range of (b)(4), with some strains exhibiting significant (b)(4).1 Your response did not indicate plans to evaluate the susceptibility of specific contaminating organisms found in media used to simulate drug products and drug products prior to sterilization against your (b)(4) sterilization process in the future.
您的回应不够充分。您指出,用于验证您的灭菌程序的那些“(b)(4)”生物体所呈现的“(b)(4)”值,大于在受污染培养基中发现的 B. cereus 生物体所呈现的“(b)(4)”值。虽然通常认为 B. cereus 的“(b)(4)”值较低,但实际上 B. cereus 的“(b)(4)”值范围相当广泛,某些菌株甚至表现出较高的“(b)(4)”值。 1 您的回应并未表明将来会评估在灭菌前用于模拟药品产品的培养基中存在的特定污染生物体对您的灭菌程序的敏感性。
You note in your response, “… (b)(4) of the (b)(4) vessels, their tubing, the manifold, and (b)(4) tubing had already been decontaminated and (b)(4). The (b)(4) vessel (ID# PDN/(b)(4)/1264) and the (b)(4) tank (ID# PDN/(b)(4)/574) which had been used to fill the (b)(4) of vials had not yet been decontaminated and (b)(4).” You failed to adequately maintain the equipment, thereby limiting your ability to ensure investigation and determination of the true root cause of the failure.
您在回复中提到:“……(b)(4)个容器、其管道、管汇以及(b)(4)个管道已经过去污处理,处于清洁状态。而用于填充小瓶子的(b)(4)个容器(编号 PDN/(b)(4)/1264)以及(b)(4)个储罐(编号 PDN/(b)(4)/574)则尚未进行去污处理。”您没有妥善维护这些设备,这限制了您查明故障真正原因的能力。
Your response acknowledges a significant adverse trend of B. cereus contamination in your facility at the time of the media fill failure and that the route of contamination may involve employee changing rooms. Notably, you also indicate that (b)(4) airborne microbial monitoring is conducted in change rooms “For Information” only. Your response does not propose a systemic review and CAPA to address your environmental monitoring program.
您的回复承认,在模拟灌装操作出现故障时,您的工厂确实存在严重的 B. cereus 污染问题。污染的来源可能是员工更衣室。此外,您还表示仅出于“提供信息”的目的,在更衣室进行了空气微生物监测。您的回复并未提出对环境监测程序的系统性审查或采取任何紧急纠正措施。
Your response provides an extended investigation into the impurities in the (b)(4) drug products. While you collaborated with your API supplier to identify the impurities and establish new specifications, adequate CAPA activities were completed only after the inspection identified the deficiency. Your response fails to include provisions for improving ongoing lifecycle oversight of suppliers.
您的回复中虽然对(b)(4)项药品中的杂质进行了详细调查,但您仅与原料药供应商合作确定了这些杂质,并制定了新的质量标准。直到检查发现缺陷之后,您才采取了适当的紧急纠正措施。您的回复并未包含改进对供应商持续监管的措施。
We acknowledge your statement that your (b)(4) air samplers are now compliant with applicable data control requirements and that you evaluated the available electronic data. However, the investigation into the aborted air samples was severely limited because of irretrievable data, resulting in an uncertain assessment of the acceptability of the environment for many marketed batches.
我们确认您所陈述的:您的(b)(4)款空气采样器现已符合相关数据控制要求;同时,您也已经对可用的电子数据进行了评估。然而,由于数据无法恢复,因此对那些被中止的空气样本的调查工作受到了严重限制,这导致对于许多已上市批次产品的环境适宜性评估变得不确定。
In response to this letter, provide:
针对这封信,请提供以下内容:
A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.
对您用于调查各种异常、差异、投诉、不合格结果和故障的整体系统进行一次全面的、独立的评估。请提供一个详细的整改计划,以修复该系统中的问题。您的整改计划应包括但不限于以下方面的改进:提升调查能力、明确调查范围、有效评估根本原因、提高 CAPA 工作的效率、加强质量监控以及完善书面程序。同时,还需要明确公司如何确保调查的各个环节都能得到妥善执行。A further investigation into the (b)(4) media fill failure that examines all potential contributing causes and includes CAPA to address them.
对(b)(4)部分模拟灌装失败问题的进一步调查,旨在找出所有可能的成因,并纳入 CAPA 机制来加以解决。An independent, comprehensive assessment of microbiological contamination risk for all distributed drug products and batches remaining within expiry that were manufactured on the (b)(4) and ampoule lines using (b)(4) tubing for (b)(4) assemblies on (b)(4) tanks.
对在使用(b)(4)管件组装的(b)(4)罐体上生产的所有已过期但仍保留在库存中的药品产品及其批次的微生物污染风险进行独立且全面的评估。Your program to assess (b)(4) of spore-forming microorganisms identified in product bioburden and the manufacturing environment for (b)(4) sterilized drug products.
请制定一个评估方案,用于检测产品中的孢子形成微生物,以及制造环境中是否存在能够产生孢子的微生物,这些微生物可能与(b)(4)项规定的无菌药品产品相关。A comprehensive, independent review of your personnel and environmental monitoring programs, including but not limited to a plan to fully remediate these programs. For example, describe changes to procedures, practices, and testing equipment that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging risks in your classified areas. Provide a timeline for implementation of your remediated program, including a summary of the steps you will be undertaking to ensure CAPA effectiveness.
对您的人员管理和环境监测计划进行全面的、独立的审查,包括但不限于制定全面修复这些计划的方案。例如,需要描述对程序、操作方式以及测试设备的改进措施,以确保持续收集有意义的数据,从而能够及时检测到新出现的风险并作出响应。同时,需要提供实施修复计划的时间表,包括为确保 CAPA 计划有效实施而将采取的步骤概述。An evaluation of the source of the (b)(4) API impurity, including CAPA that address the need to develop full impurity profiles for your supplier’s APIs.
对(b)(4)项 API 中杂质来源的评估,包括相关 CAPA 措施,以满足为供应商的 API 开发完整杂质谱的需求。A comprehensive assessment of your air samplers and how you will ensure data will be retained and reviewed. Also provide an update on your impact assessment relating to the lost data.
对您的空气采样设备进行全面评估,同时确定如何确保数据的保存和审查。请同时提供关于丢失数据相关的影响评估的最新情况。A comprehensive, independent assessment of electronic and paper-based documentation systems in manufacturing and laboratory operations, to identify insufficient documentation practices. Include a detailed CAPA plan to remediate data review practices and to ensure attributable, legible, complete, original, accurate, contemporaneous records.
对制造和实验室操作中的电子和纸质文档系统进行全面、独立的评估,以发现存在不足的文档管理实践。需要制定详细的 CAPA 计划来改进数据审查流程,确保记录具有可归因性、可读性、完整性、原始性、准确性,并且是及时的。A comprehensive, independent assessment and CAPA plan for computer-system security and integrity. Include a report identifying design and control vulnerabilities and the appropriate remediations for each of your laboratory and manufacturing computer systems.
一份全面的、独立的评估报告,针对计算机系统的安全性和完整性提出改进建议。报告将指出各实验室和制造系统中的设计缺陷与控制漏洞,并提出相应的修复方案。Clarify whether you will continue to use (b)(4) suppliers of (b)(4) API, and what standards will be required of these suppliers, including but not limited to, impurities.
请明确是否将继续使用(b)(4)条款中列出的 API 供应商,以及这些供应商需要满足哪些标准,包括但不限于杂质方面的要求。
来源:BasicPharma搬砖工 · mp.weixin.qq.com